Welcome to our dedicated page for CeriBell news (Ticker: CBLL), a resource for investors and traders seeking the latest updates and insights on CeriBell stock.
CeriBell, Inc. develops medical technology for diagnosing and monitoring serious neurological conditions in acute-care settings. Its Ceribell System is a point-of-care electroencephalography, or EEG, platform that combines portable hardware with AI-powered algorithms for rapid brain monitoring in hospitals. The system is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S.
Company updates commonly address quarterly and annual financial results, adoption of the Ceribell System, FDA clearances for the Clarity algorithm and delirium monitoring, and regulatory designations tied to additional neurological indications such as large vessel occlusion stroke. Ceribell also issues announcements on investor conference participation and other public-company communications.
Ceribell (Nasdaq: CBLL) announced that the U.S. Centers for Medicare & Medicaid Services has granted a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible Medicare inpatient case for use of the Ceribell Delirium Monitor System, effective October 1, 2026.
The NTAP follows the system’s December 2025 FDA 510(k) clearance as the first and only FDA-cleared device to aid in delirium screening and monitoring. Built on Ceribell’s existing point-of-care EEG technology for detecting nonconvulsive seizures and electrographic status epilepticus, the unified platform now supports both seizure and delirium monitoring in a single bedside system for critically ill patients.
Ceribell (Nasdaq: CBLL) appointed Thomas “Tom” West and Sharon O’Keefe to its Board of Directors as the company continues expanding adoption of its point-of-care brain monitoring platform, which is now deployed in more than 680 U.S. hospitals.
West brings extensive medtech commercialization experience, having served as President and CEO of Nalu Medical, acquired by Boston Scientific for $600 million in January 2026, and of Intersect ENT, acquired by Medtronic for $1.1 billion. He also previously held senior roles at Hologic and Johnson & Johnson and serves on multiple healthcare company boards. O’Keefe offers deep health-system operating expertise, most recently as President of the University of Chicago Medical Center and COO of the University of Chicago Medicine health system, overseeing more than $2 billion in annual operating revenue, and holding prior leadership roles at several major academic medical centers.
Ceribell (Nasdaq: CBLL) announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston. The session is scheduled for Wednesday, August 12, 2026, at 6:00 a.m. PDT / 9:00 a.m. EDT, with a live and archived webcast available in the Investor Relations section of the Ceribell website.
Ceribell (Nasdaq: CBLL) will release its second quarter 2026 financial results after market close on Monday, August 10, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, with live dial-in options and webcast access via the company’s investor relations website.
Ceribell (Nasdaq: CBLL) reported a new Critical Care Medicine publication linking its Clarity AI seizure-burden metric with neurological outcomes at discharge. The multicenter study of 359 adults across three academic hospitals found higher AI-detected seizure burden was associated with greater odds of severe disability or death.
Patients with peak 5-minute seizure burden ≥90% were 3.4 times more likely to have death or severe disability versus 0% burden, and each additional hour of Clarity-assessed seizure nearly doubled this risk (adjusted odds ratio 1.98). The paper is Open Access.
Ceribell (Nasdaq: CBLL) announced that CEO and Co-founder Jane Chao, Ph.D., will present at the William Blair 46th Annual Growth Stock Conference in Chicago.
The presentation is scheduled for Wednesday, June 3, 2026, at 9:20 a.m. PDT / 11:20 a.m. CDT, with a live and archived webcast available in the Investor Relations section of Ceribell’s website.
Ceribell (Nasdaq: CBLL) reported first quarter 2026 revenue of $26.5 million, up 29% year over year, with 680 active accounts and 87% gross margin. Product revenue reached $20.2 million and subscription revenue $6.3 million.
Operating expenses rose to $43.9 million, driving a net loss of $19.7 million ($0.52 per share). Cash, cash equivalents, and marketable securities totaled $141.2 million. Ceribell launched neonate and pediatric products, received a supportive CMS proposed rule for NTAP delirium monitoring reimbursement, and raised 2026 revenue guidance to $112–$116 million, implying 26%–30% growth over 2025.
Ceribell (Nasdaq: CBLL) announced that CEO and co‑founder Jane Chao, Ph.D., and CFO Scott Blumberg will take part in a fireside chat at the Bank of America Securities 2026 Health Care Conference.
The event is scheduled for Wednesday, May 13, 2026 at 3:40 p.m. PST / 6:40 p.m. EST. According to Ceribell, a live and archived webcast will be available in the company's Investor Relations section at https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) will report its first quarter 2026 financial results after market close on Monday, May 11, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss results.
Investors can join by phone (domestic: (800) 715-9871; international: (646) 307-1963; access code 1880547) or via a live and archived webcast in the company's Investor Relations website at https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) reported fourth-quarter and full-year 2025 results, delivering $24.8M revenue in Q4 (+34% YoY) and $89.1M for 2025 (+36% YoY). Gross margin was 87% Q4 and 88% FY. FY operating expenses rose 42% to $136.7M and net loss was $53.4M. Ceribell received multiple FDA clearances including a continuous monitoring solution, neonatal Clarity clearance, and Breakthrough Device designation for LVO stroke detection. Cash and marketable securities totaled $159.3M. 2026 revenue guidance is $111M–$115M (≈25%–29% growth).